The COVID-19 outbreak has led the US FDA’s Center for Drug Evaluation and Research to dip its toes into the virtual advisory committee waters with a two-day panel review of pediatric development plans for four oncologic agents.
On 17-18 June, the Oncologic Drugs Advisory Committee’s pediatric oncology subcommittee will convene online to discuss issues related to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?